Inhaled nitric oxide in 2003: A review of its mechanisms of action

Canadian Journal of Anesthesia

Volumn 50, Issue 8, 2003, Pages 839-846

  Wang, Tianglong ^a   El Kebir, Driss ^a   Blaise, Gilbert ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; BOSENTAN; BRONCHODILATING AGENT; DIPYRIDAMOLE; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; MILRINONE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; SILDENAFIL; VASODILATOR AGENT; VIANOX; ZAPRINAST;

BLOOD CLOTTING; CLINICAL TRIAL; CYANOSIS; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENTIATION; DYSPNEA; ENERGY METABOLISM; FIBRINOLYSIS; GAS TRANSPORT; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS; LUNG BLOOD VESSEL; LUNG INJURY; LUNG PERFUSION; METABOLIC DISORDER; METHEMOGLOBINEMIA; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC CIRCULATION; THROMBOCYTE FUNCTION; URINE VOLUME; VASODILATATION;

EID: 0345688852     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03019384     Document Type: Review

References (91)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9.
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
5. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915-8.
6. Tiefenbacher CP. Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction? Am J Physiol Heart Circ Physiol 2001; 280: H2484-8.
7. Blaise G. The endothelium at rest. In: Spiess (Ed.). The Relationship Between Coagulation, Inflammation, and Endothelium - A Pyramid Towards Outcome. Baltimore: Lippincott Williams & Wilkins; 2000: 31-78.
8. Kolesnikov YA, Pan YX, Babey AM, Jain S, Wilson R, Pasternak GW. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Proc Natl Acad Sci USA 1997; 94: 8220-5.
9. Liu HW, Anand A, Bloch K, Christiani D, Kradin R. Expression of inducible nitric oxide synthase by macrophages in rat lung. Am J Respir Crit Care Med 1997; 156: 223-8.
10. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993; 54: 171-8.
11. Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci USA 1995; 92: 7809-13.
12. Belvisi MG, Stretton CD, Yacoub M, Barnes PJ. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992; 210: 221-2.
13. Lundberq JQ, Lundberg JM, Settergren G, Alving K, Weitzberg E. Nitric oxide, produced in the upper airways, may act in an 'aerocrine' fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol Scand 1995; 155: 467-8.
14. Chambers DC, Carpenter DA, Ayres JG. Exchange dynamics of nitric oxide in the human nose. J Appl Physiol 2001; 91: 1924-30.
15. Dillon WC, Hampl V, Shultz PJ, Rubins JB, Archer SL. Origins of breath nitric oxide in humans. Chest 1996; 110: 930-8.
16. Hogman M, Frostell CG, Hedenstrom H, Hedenstierna G. Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Respir Dis 1993; 148: 1474-8.
17. Lundberg JO, Sattergren G, Gelinder S, Lundberg JM, Alving K, Weitzberg E. Inhalation of nasally derived nitric oxide modulates pulmonary function in humans. Acta Physiol Scand 1996; 158: 343-7.
18. Francoe M, Troncy E, Blaise G. Inhaled nitric oxide: technical aspects of administration and monitoring. Crit Care Med 1998; 26: 782-96.
19. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002; 359: 1781-2.
20. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414.
21. Hanafy KA, Krumenacker JS, Murad F. NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit 2001; 7: 801-19.
22. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8.
23. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038-47.
24. Van Obbergh LJ, Charbonneau M, Blaise G. Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth 1996; 77: 227-31.
25. Alam MS, Akaike T, Okamoto S, et al. Role of nitric oxide in host defense in murine salmonellosis as a function of its antibacterial and antiapoptotic activities. Infect Immun 2002; 70: 3130-42.
26. Jain B, Rubinstein I, Robbins RA, Leise KL, Sisson JH. Modulation of airway epithelial cell ciliary beat frequency by nitric oxide. Biochem Biophys Res Commun 1993; 191: 83-8.
27. Ramnarine SI, Khawaja AM, Barnes PJ, Rogers DF. Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea in vitro. Br J Pharmacol 1996; 118: 998-1002.
28. Nagaki M, Shimura MN, Irokawa T, Sasaki T, Shirato IC. Nitric oxide regulation of glycoconjugate secretion from feline and human airways in vitro. Respir Physiol 1995; 102: 89-95.
29. Higenbottam T, Siddons T, Demoncheaux E. A therapeutic role for chronic inhaled nitric oxide? Lancet 2000; 356: 446-7.
30. Fratacci MD, Frostell CG, Chen TY, Wain JC Jr, Robinson DR, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75: 990-9.
31. Malmros C, Blomquist S, Dahm P, Martensson L, Thorne J. Nitric oxide inhalation decreases pulmonary platelet and neutrophil sequestration during extracorporeal circulation in the pig. Crit Care Med 1996; 24: 845-9.
32. Adrie C, Bloch KD, Moreno PR, et al. Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation 1996; 94: 1919-26.
33. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and cridothelial dysfunction in atherosclerosis. Vascul Pharmacol 2002; 38: 259-69.
34. Jugdutt BI. Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev 2002; 7: 391-405.
35. Leopold JA, Loscalzo J. New developments in nitrosovasodilator therapy. Vasc Med 1997; 2: 190-202.
36. Bloomfield GL, Holloway S, Ridings PC, et al. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med 1997; 25: 584-93.
37. Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo MA, Payen DM. Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996; 153: 985-90.
38. Rubbo H, Radi R, Anselmi D, et al. Nitric oxide reaction with lipid peroxyl radicals spares α-tocopherol during lipid peroxidation. Greater oxidant protection from the pair nitric oxide/α-tocopherol than α-tocopherol/ascorbate. J Biol Chem 2000; 275: 10812-8.
39. Baldus S, Castro L, Eiserich JP, Freeman BA. Is NO news bad news in acute respiratory distress syndrome? Am J Respir Crit Care Med 2001; 163: 308-10.
40. Sittipunt C, Steinberg KP, Ruzinski JT, et al. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163: 503-10.
41. Colasanti M, Persichini T. Nitric oxide: an inhibitor of NF-κB/Rel system in glial cells. Brain Res Bull 2000; 52: 155-61.
42. Laroux FS, Pavlick KP, Hines IN, et al. Role of nitric oxide in inflammation. Acta Physiol Scand 2001; 173: 113-8.
43. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93: 9114-9.
44. Kupatt C, Weber C, Wolf DA, Becker BF, Smith TW, Kelly RA. Nitric oxide attenuates reoxygenation-induced ICAM-1 expression in coronary microvascular endothelium: role of NFκB. J Mol Cell Cardiol 1997; 29: 2599-609.
45. Shin WS, Hong TH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-γ. The role of constitutive NF-κB activity. J Biol Chem 1996; 271: 11317-24.
46. Spiecker M, Peng HB, Liao JK. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IκBα. J Biol Chem 1997; 272: 30969-74.
47. Spiecker M, Darius H, Kaboth K, Hubner F, Liao JK. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol 1998; 63: 732-9.
48. 2 biosynthesis in macrophages. J Leukoc Biol 1999; 65: 792-9.
49. Sheffler LA, Wink DA, Melillo G, Cox GW. Exogenous nitric oxide regulates IFN-γ plus lipopolysaccharide-induced nitric oxide synthase expression in mouse macrophages. J Immunol 1995; 155: 886-94.
50. Hubert BP, Blaise GA. Inhaled NO given perioperatively improves oxygenation and decreases pulmonary arterial resistance following cardiopulmonary bypass in a pig model. Anesthesiology 2001; 95: A-366 (abstract).
51. Hubert BP, Radomski M, Blaise GA. Does inhaled nitric oxide (inhNO) affect matrix-metalloproteinase (MMP) concentration in bronchoalveolar lavage fluid (BAL) after cardiopulmonary bypass (CPB)? Anesthesiology 2001; 95: A-440 (abstract).
52. Friese RS, Fullerton DA, McIntyre RC Jr, et al. NO prevents neutrophil-mediated pulmonary vasomotor dysfunction in acute lung injury. J Surg Res 1996; 63: 23-8.
53. Neviere R, Guery B, Mordon S, et al. Inhaled NO reduces leukocyte-endothelial cell interactions and myocardial dysfunction in endotoxemic rats. Am J Physiol Heart Circ Physiol 2000; 278: H1783-90.
54. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000; 356: 1464-9.
55. Gross SS. Vascular biology. Targeted delivery of nitric oxide. Nature 2001; 409: 577-8.
56. Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide bioactivity. Nature 2001; 409: 622-6.
57. Ramachandran N, Root P, Jiang XM, Hogg PJ, Mutus B. Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase. Proc Natl Acad Sci USA 2001; 98: 9539-44.
58. Modin A, Bjorne H, Herulf M, Alving K, Weitzberg E, Lundberg JO. Nitrite-derived nitric oxide: a possible mediator of 'acidic-metabolic' vasodilation. Acta. Physiol Scand 2001; 171: 9-16.
59. Cannon RO III, Schechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest 2001; 108: 279-87.
60. Troncy E, Francoeur M, Salazkin I, et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br J Anaesth 1997; 79: 631-40.
61. Wraight WM, Young JD. Renal effects of inhaled nitric oxide in humans. Br J Anaesth 2001; 86: 267-9.
62. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001; 59: 5-16.
63. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271: C1424-37.
64. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995; 268: L699-722.
65. van der Vliet A, Eiserich JP, Shigenaga MK, Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract. Epiphenomena or a pathobiologic mechanism of disease? Am J Respir Crit Care Med 1999; 160: 1-9.
66. Haddad IY, Zhu S, Crow J, Barefield E, Gadilhe T, Matalon S. Inhibition of alveolar type II cell ATP and surfactant synthesis by nitric oxide. Am J Physiol 1996; 270: L898-906.
67. Knepler JL Jr, Taher LN, Gupta MP, et al. Peroxynitrite causes endothelial cell monolayer barrier dysfunction. Am J Physiol Cell Physiol 2001; 281: C1064-75.
68. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 1997; 100: 723-35.
69. Zouki C, Zhang SL, Chan JS, Filep JG. Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J 2001; 15: 25-7.
70. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89: 684-91.
71. Szabo C, Billiar TR. Novel roles of nitric oxide in hemorrhagic shock. Shock 1999; 12: 1-9.
72. Black SM, Heidersbach RS, McMullan DM, Bekker JM, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am J Physiol 1999; 277: H1849-56.
73. Dotsch J, Demirakca S, Zepf K, Hanze J, Parida S, Rascher W. Recovery from withdrawal of inhaled nitric oxide and kinetics of nitric oxide-induced inhibition of nitric oxide synthase activity in vitro. Intensive Care Med 2000; 26: 330-5.
74. McMullan DM, Bekker JM, Johengen MJ, et al. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1. Am J Physiol Heart Circ Physiol 2001; 280: H777-85.
75. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001; 89: 357-64.
76. Sheehy AM, Burson MA, Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol 1998; 274: L833-41.
77. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome. A pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157: 1483-8.
78. Jacobs BR, Brilli RJ, Ballard ET, Passerini DJ, Smith DJ. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Am J Respir Crit Care Med 1998; 158: 1536-42.
79. Brilli RJ, Krafte-Jacobs B, Smith DJ, Passerini D, Moore L, Ballard ET. Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension. Crit Care Med 1998; 26: 1390-6.
80. Adrie C, Ichinose F, Holzmann A, Keefer L, Hurford WE, Zapol WM. Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension. J Appl Physiol 1998; 84: 435-41.
81. Meadow W, Rudinsky B, Bell A, Hipps R. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Pediatr Res 1998; 44: 181-6.
82. Schutte H, Grimminger F, Otterbein J, et al. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther 1997; 282: 985-94.
83. Gong F, Shiraishi H, Kikuchi Y, et al. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619. Pediatr Int 2000; 42: 255-8.
84. Palhares DB, Figueiredo CS, Moura AJ. Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns. J Perinat Med 1998; 26: 219-24.
85. Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998; 88: 410-6.
86. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29: 1000-5.
87. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.
88. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-45.
89. Haraldson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114: 780-6.
90. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-82.
91. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999; 86: 1160-4.